Pfizer's launch of the inhaled insulin Exubera is slated for June, Human Health President Karen Katen said during an investor meeting Feb. 10. The company had previously said the timeline for launch was mid-year due to supply chain issues, the need for physician education and reimbursement discussions (1"The Pink Sheet" Feb. 13, 2006, p. 23). Katen noted that Pfizer has not yet announced Exubera's pricing but stated "we will possibly announce it" prior to the June lunch. Exubera was approved Jan. 27 for the treatment of adults with type 1 and type 2 diabetes...
You may also be interested in...
Pfizer's mid-year launch timeline for its inhaled insulin therapy Exubera is influenced by the need to educate physicians, complex supply chain issues and reimbursement discussions, Pfizer co-development partner Nektar suggested
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.